Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 103, Issue 43, 2006, Pages 15975-15980

  Thijssen, Victor L J L ^a   Postel, Ruben ^b   Brandwijk, Ricardo J M G E ^a   Dings, Ruud P M ^c   Nesmelova, Irina ^c   Satijn, Sietske ^a   Verhofstad, Nicole ^a   Nakabeppu, Yusaku ^d   Baum, Linda G ^e   Bakkers, Jeroen ^b   Mayo, Kevin H ^c   Poirier, Françoise ^f   Griffioen, Arjan W ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b CBS KNAW FUNGAL BIODIVERSITY CENTRE   (Netherlands)

^c UNIVERSITY OF MINNESOTA   (United States)

^d KYUSHU UNIVERSITY   (Japan)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f CNRS   (France)

Author keywords

Anginex; Angiostatic therapy; Endothelial cell; Galectin; Tumor models

Indexed keywords

ANGINEX; ANGIOGENESIS INHIBITOR; GALECTIN 1; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG TARGETING; EMBRYO; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; ZEBRA FISH;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DISEASE PROGRESSION; ENDOTHELIAL CELLS; GALECTIN 1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, KNOCKOUT; NEOPLASM TRANSPLANTATION; NEOPLASMS; PROTEIN BINDING; PROTEINS; ZEBRAFISH;

DANIO RERIO;

EID: 33750474852     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.0603883103     Document Type: Article

References (46)

1. Folkman J (1972) Ann Surg 175:409-416.
2. Griffioen AW, Molema G (2000) Pharmacol Rev 52:237-268.
3. van Beijnum JR, Griffioen AW (2005) Biochim Biophys Acta 1755:121-134.
4. Griffioen AW, van der Schaft DW, Barendsz-Janson AF, Cox A, Struijker Boudier HA, Hillen HF, Mayo KH (2001) Biochem J 354:233-242.
5. van der Schaft DW, Dings RP, de Lussanet QG, van Eijk LI, Nap AW, Beets-Tan RG, Bouma-Ter Steege JC, Wagstaff J, Mayo KH, Griffioen AW (2002) FASEB J 16:1991-1993.
6. Dings RP, van der Schaft DW, Hargittai B, Haseman J, Griffioen AW, Mayo KH (2003) Cancer Lett 194:55-66.
7. Drickamer K (1988) J Biol Chem 263:9557-9560.
8. Hirabayashi J, Kasai K (1993) Glycobiology 3:297-304.
9. Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, Gitt MA, Hirabayashi J, Hughes C, Kasai K, et al. (1994) Cell 76:597-598.
10. Cooper DN (2002) Biochim Biophys Acta 1572:209-231.
11. Houzelstein D, Goncalves IR, Fadden AJ, Sidhu SS, Cooper DN, Drickamer K, Leffler H, Poirier F (2004) Mol Biol Evol 21:1177-1187.
12. Hughes RC (2001) Biochimie 83:667-676.
13. Scott K, Weinberg C (2004) Glycoconj J 19:467-477.
14. Perillo NL, Pace KE, Seilhamer JJ, Baum LG (1995) Nature 378:736-739.
15. Park JW, Voss PG, Grabski S, Wang JL, Patterson RJ (2001) Nucleic Acids Res 29:3595-3602.
16. Brandwijk RJ, Nesmelova I, Dings RP, Mayo KH, Thijssen VL, Griffioen AW (2005) Biochem Biophys Res Commun 333:1261-1268.
17. Lawson ND, Weinstein BM (2002) Dev Biol 248:307-318.
18. Ahmed H, Du SJ, O'Leary N, Vasta GR (2004) Glycobiology 14:219-232.
19. Poirier F, Robertson EJ (1993) Development (Cambridge, UK) 119:1229-1236.
20. Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, Mordoh J, Fainboim L, Podhajcer OL, Rabinovich GA (2004) Cancer Cell 5:241-251.
21. Dings RP, Yokoyama Y, Ramakrishnan S, Griffioen AW, Mayo KH (2003) Cancer Res 63:382-385.
22. Lotan R, Belloni PN, Tressler RJ, Lotan D, Xu XC, Nicolson GL (1994) Glycoconj J 11:462-468.
23. Clausse N, van den Brule F, Waltregny D, Gamier F, Castronovo V (1999) Angiogenesis 3:317-325.
24. McGraw J, McPhail LT, Oschipok LW, Horie H, Poirier F, Steeves JD, Ramer MS, Tetzlaff W (2004) Eur J Neurosci 20:2872-2880.
25. McGraw J, Gaudet AD, Oschipok LW, Steeves JD, Poirier F, Tetzlaff W, Ramer MS (2005) Pain 114:7-18.
26. Klagsbrun M, Eichmann A (2005) Cytokine Growth Factor Rev 16:535-548.
27. Weinstein BM (2005) Cell 120:299-302.
28. Puche AC, Poirier F, Hair M, Bartlett PF, Key B (1996) Dev Biol 179:274-287.
29. Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, Raz A (2000) Am J Pathol 156:899-909.
30. Kuklinski S, Vladimirova V, Waha A, Kamata H, Pesheva P, Probstmeier R (2003) J Neurochem 87:1112-1124.
31. Zou J, Glinsky VV, Landon LA, Matthews L, Deutscher SL (2005) Carcinogenesis 26:309-318.
32. Liu FT, Rabinovich GA (2005) Nat Rev Cancer 5:29-41.
33. van den Brule F, Califice S, Castronovo V (2004) Glycoconj J 19:537-542.
34. Akerman ME, Pilch J, Peters D, Ruosiahti E (2005) Proc Natl Acad Sci USA 102:2040-2045.
35. Allen HJ, Sucato D, Woynarowska B, Gottstine S, Sharma A, Bernacki RJ (1990) J Cell Biochem 43:43-57.
36. Gabius HJ, Brehler R, Schauer A, Cramer F (1986) Virchows Arch B Cell Pathol Ind Mol Pathol 52:107-115.
37. van den Brule FA, Waltregny D, Castronovo V (2001) J Pathol 193:80-87.
38. Lotan R, Matsushita Y, Ohannesian D, Carralero D, Ota DM, Cleary KR, Nicolson GL, Irimura T (1991) Carbohydr Res 213:47-57.
39. Pace KE, Hahn HP, Baum LG (2003) Methods Enzymol 363:499-518.
40. Thijssen VL, Brandwijk RJ, Dings RP, Griffioen AW (2004) Exp Cell Res 299:286-293.
41. de Lussanet QG, Backes WH, Griffioen AW, Padhani AR, Baeten CI, van Baardwijk A, Lambin P, Beets GL, van Engelshoven JM, Beets-Tan RG (2005) Int J Radiat Oncol Biol Phys 63:1309-1315.
42. Harder R, Uhlig H, Kashan A, Schutt B, Duijvestijn A, Butcher EC, Thiele HG, Hamann A (1991) Exp Cell Res 197:259-267.
43. Nasevicius A, Larson J, Ekker SC (2000) Yeast 17:294-301.
44. Hammerschmidt M, Pelegri F, Mullins MC, Kane DA, Brand M, van Eeden FJ, Furutani-Seiki M, Granato M, Haffter P, Heisenberg CP, et al. (1996) Development (Cambridge, UK) 123:143-151.
45. Larson JD, Wadman SA, Chen E, Kerley L, Clark KJ, Eide M, Lippert S, Nasevicius A, Ekker SC, Hackett PB, Essner JJ (2004) Dev Dyn 231:204-213.
46. Isogai S, Horiguchi M, Weinstein BM (2001) Dev Biol 230:278-301.